,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-11-27 08:46:00,Hedge fund’s Q3 trades are now public following the release of 13F forms filed with the SEC.,0.012486711144447327,0.03799770027399063,0.9495155215263367,neutral,-0.025510989129543304
1,2017-11-27 08:46:00,"For investors, this means that now is the time to track the “Smart Money” of hedge fund gurus like Warren Buffett and Carl Icahn.",0.32254788279533386,0.08278732001781464,0.5946648120880127,neutral,0.23976056277751923
2,2017-11-27 08:46:00,"And with the innovative Nasdaq Smart Portfolio stock screener, you can easily pinpoint top stocks that match your investment criteria.",0.3360774517059326,0.009051835164427757,0.6548706889152527,neutral,0.3270256221294403
3,2017-11-27 08:46:00,"The screener has a database of over 5,000 stocks as well as multiple filter options.",0.020038021728396416,0.007653571665287018,0.9723083972930908,neutral,0.012384450063109398
4,2017-11-27 08:46:00,Here we searched for stocks with both a positive hedge fund signal and a ‘Strong Buy’ best analyst consensus.,0.7831768989562988,0.03435148671269417,0.18247154355049133,positive,0.7488254308700562
5,2017-11-27 08:46:00,"Using our big data analytics, we can also track the stock’s overall outlook from the Street.",0.08883007615804672,0.00584426848217845,0.9053256511688232,neutral,0.08298581093549728
6,2017-11-27 08:46:00,This gives us a better idea of whether these stocks make compelling investment opportunities.,0.49266108870506287,0.011124894954264164,0.4962139427661896,neutral,0.4815361797809601
7,2017-11-27 08:46:00,"Bearing that in mind, let’s now take a closer look at these 3 top stocks.",0.04483893886208534,0.00845559872686863,0.9467054009437561,neutral,0.036383338272571564
8,2017-11-27 08:46:00,Salesforce.com (CRM) - Cloud computing giant Salesforce is a top hedge fund stock right now.,0.67887943983078,0.017551803961396217,0.3035687208175659,positive,0.6613276600837708
9,2017-11-27 08:46:00,"In the last quarter, hedge funds increased holdings by a net total of 1.6 million shares.",0.906998336315155,0.013625659048557281,0.07937609404325485,positive,0.893372654914856
10,2017-11-27 08:46:00,Big-name fund gurus that leapt into the stock include Ray Dalio and Steve Mandel of the $20 billion Lone Pine Capital LLC fund.,0.11239588260650635,0.015566125512123108,0.8720380067825317,neutral,0.09682975709438324
11,2017-11-27 08:46:00,In the last quarter he ramped up his CRM holding by 137% to over $585 million.,0.9262089729309082,0.013093517161905766,0.06069754809141159,positive,0.9131154417991638
12,2017-11-27 08:46:00,"However, Frank Sands still takes first place with a massive $1.25 billion position.",0.38045141100883484,0.012239638715982437,0.6073089838027954,neutral,0.3682117760181427
13,2017-11-27 08:46:00,And hedge funds aren’t alone in their bullish sentiment.,0.13490085303783417,0.11478391289710999,0.7503151893615723,neutral,0.020116940140724182
14,2017-11-27 08:46:00,The Street also has a ‘Strong Buy’ analyst consensus rating on CRM with an average price target of $119 (10.8% upside potential).,0.8794108629226685,0.01615220308303833,0.10443692654371262,positive,0.8632586598396301
15,2017-11-27 08:46:00,CRM is “gobbling up the cloud with another strong quarter and outlook” writes top Drexel Hamilton analyst Brian White on November 22.,0.906040608882904,0.034098315984010696,0.05986114591360092,positive,0.8719422817230225
16,2017-11-27 08:46:00,He boosted his price target from $120 all the way to $129 (20% upside potential) following the company’s very strong Q3 results and guidance.,0.940768837928772,0.01960582286119461,0.03962542489171028,positive,0.921163022518158
17,2017-11-27 08:46:00,"“In our view, the cloud trend remains in the early stages and we believe Salesforce represents the best vehicle for investors to play the cloud trend as the company moves toward its $20-22 billion revenue milestone” says White.",0.7899284362792969,0.013093182817101479,0.19697844982147217,positive,0.7768352627754211
18,2017-11-27 08:46:00,He recommends buying the stock on any weakness.,0.2330314964056015,0.022057393565773964,0.7449111342430115,neutral,0.2109740972518921
19,2017-11-27 08:46:00,"For the quarter, CRM beat on all key metrics with 3Q:FY18 revenue of $2.680 billion (up 25% YoY) vs Street consensus of $2.650 billion and EPS of $0.39 (Street was at $0.37).",0.9439666867256165,0.03358390927314758,0.022449420765042305,positive,0.9103827476501465
20,2017-11-27 08:46:00,Applied Materials (AMAT)- Chip gear maker AMAT is ticking all the boxes.,0.048379842191934586,0.07741383463144302,0.8742063641548157,neutral,-0.029033992439508438
21,2017-11-27 08:46:00,"In Q3, hedge funds snapped up 5.9 million more Applied Materials shares.",0.839469313621521,0.03660988807678223,0.12392069399356842,positive,0.8028594255447388
22,2017-11-27 08:46:00,Zero hedge funds exited the stock and only 5 reduced positions vs 18 who increased holdings.,0.0891771912574768,0.8212500214576721,0.08957283198833466,negative,-0.7320728302001953
23,2017-11-27 08:46:00,UK-based fund manager Egerton’s John Armitage upped his position by 23% to $883 million- making this the fund’s third biggest stock after Comcast and Charter Communications.,0.9442043304443359,0.028036760166287422,0.02775898016989231,positive,0.9161675572395325
24,2017-11-27 08:46:00,"“Every Year is a Peak Year for Gary’s [CEO Gary Dickerson] AMAT,” comments Credit Suisse’s Farhan Ahmad.",0.6799079179763794,0.07529512047767639,0.24479693174362183,positive,0.6046128273010254
25,2017-11-27 08:46:00,He reiterated his buy rating on AMAT on November 17 with a $72 price target (27% upside potential) following the stock’s strong fiscal fourth quarter results and upbeat guidance.,0.8951649069786072,0.015149165876209736,0.08968602120876312,positive,0.8800157308578491
26,2017-11-27 08:46:00,Ahmad dismisses the idea that AMAT is a “pure cyclical company”.,0.03009805642068386,0.44067689776420593,0.5292250514030457,neutral,-0.4105788469314575
27,2017-11-27 08:46:00,"Instead, he sees Applied Materials as very much a ""growth company"" with a ""solid"" history of buybacks.",0.7590349912643433,0.011089840903878212,0.22987517714500427,positive,0.7479451298713684
28,2017-11-27 08:46:00,"During the past 12 years, AMAT has managed to reduce its share count by 35% and is planning a further 6% reduction for the next three years.",0.019092410802841187,0.9665094614028931,0.014398174360394478,negative,-0.9474170207977295
29,2017-11-27 08:46:00,Overall AMAT boasts an impressive 15 consecutive buy ratings from analysts in the last three months.,0.9530559778213501,0.017162345349788666,0.029781607910990715,positive,0.9358936548233032
30,2017-11-27 08:46:00,"And with a $64.53 average price target, analysts are predicting AMAT can climb 11.43% over the next 12 months.",0.9403507113456726,0.020674312487244606,0.03897500038146973,positive,0.9196764230728149
31,2017-11-27 08:46:00,Incyte Corporation (INCY)- Fund managers refuse to give up on oncology pharma Incyte.,0.04888765886425972,0.8345526456832886,0.116559699177742,negative,-0.785664975643158
32,2017-11-27 08:46:00,Prices for INCY plunged from $138 in August to the current share price of just under $100 after Gilead Sciences (GILD) snapped up cancer therapy developer Kite Pharma for $11.9 billion instead of Incyte.,0.018330488353967667,0.9668324589729309,0.014837019145488739,negative,-0.9485019445419312
33,2017-11-27 08:46:00,"But if we turn to TipRanks, the hedge fund confidence signal for Q3 is still ‘very positive’ based on 18 hedge fund transactions.",0.8448880910873413,0.02786261960864067,0.12724930047988892,positive,0.8170254826545715
34,2017-11-27 08:46:00,"In terms of the number of shares held by the Smart Money, hedge funds increased holdings in the quarter by a net total of 1.2 million shares.",0.9270294308662415,0.015349440276622772,0.05762102082371712,positive,0.9116799831390381
35,2017-11-27 08:46:00,"Renown fund managers like Arthur Cohen, Andrew Law and Joel Greenblatt all initiated new positions in the stock.",0.16291703283786774,0.009456817992031574,0.8276261687278748,neutral,0.15346021950244904
36,2017-11-27 08:46:00,"For example, Arthur Cohen’s health-focused fund now has a $70 million stake in INCY.",0.048840656876564026,0.0056866914965212345,0.9454726576805115,neutral,0.04315396398305893
37,2017-11-27 08:46:00,"Meanwhile, even with a 5% trim, Frank Sands remains the stock’s biggest shareholder with a huge $883 million position.",0.3879631757736206,0.017402008175849915,0.5946348309516907,neutral,0.3705611824989319
38,2017-11-27 08:46:00,INCY has also clung on to its ‘Strong Buy’ analyst consensus rating.,0.9407636523246765,0.0276456568390131,0.031590647995471954,positive,0.9131180047988892
39,2017-11-27 08:46:00,"In the last three months, the stock has received six buy ratings versus just 1 hold rating from top analysts.",0.6804307699203491,0.03775739297270775,0.2818118631839752,positive,0.6426733732223511
40,2017-11-27 08:46:00,"The icing on the cake: with share prices now at $98, analysts are predicting big upside for INCY of over 54%.",0.9112492799758911,0.043963972479104996,0.04478676989674568,positive,0.8672853112220764
41,2017-11-27 08:46:00,"“With one of the deepest/broadest immune-oncology pipelines in the sector, the added flexibility of an in-house PD-1 inhibitor and a potentially first in class oncology asset with an important value inflecting catalyst in the first half of 2018, we think that INCY represents an attractive opportunity with strategic value,” commented JP Morgan analyst Cory Kasimov at the end of October.",0.8925854563713074,0.012235045433044434,0.09517953544855118,positive,0.8803504109382629
42,2017-11-27 08:46:00,His bullish sentiment is reflected in his buy rating and $149 price target.,0.1547711342573166,0.0123768774792552,0.8328519463539124,neutral,0.1423942595720291
43,2017-11-27 08:46:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
44,2017-11-27 08:46:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
